Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00362492
Other study ID # PHRC-Prothege
Secondary ID
Status Completed
Phase Phase 4
First received August 9, 2006
Last updated October 27, 2010
Start date June 2004
Est. completion date June 2007

Study information

Verified date October 2010
Source University Hospital, Caen
Contact n/a
Is FDA regulated No
Health authority France: Health Ministry
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement. The investigators select patients without proximal thromboembolism assessed by bilateral venous ultrasound examination 7-10 days after surgery. the investigators hypothesis is that stopping thromboprophylaxis is equally effective than prolonging thromboprophylaxis in order to prevent post-surgery complications in this population.


Recruitment information / eligibility

Status Completed
Enrollment 850
Est. completion date June 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 46 Years and older
Eligibility Inclusion Criteria:

- First total knee joint replacement

- Signed informed consent

Non-inclusion Criteria:

- History of venous thromboembolism/major bleeding/Heparin induced thrombopenia

- Active cancer

- Long-term anticoagulation

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Procedure:
Bilateral ultrasound examination 7+/- 2 after surgery


Locations

Country Name City State
France Hospital Alençon Alençon
France Hospital University Angers Angers
France Clinique du Cèdre Bois-Guillaume
France Caen University hospital Caen
France Clinique St Marie Chalons sur Saone
France Hospital Val D'ariège Foix
France Hospital La Roche sur Yon La Roche sur Yon
France Mignot Hospital Le Chesnay
France Polyclinique de Riaumont Lievin
France Hospital University Lille Lille
France Hospital Nord Mayenne Mayenne
France Montluçon Hospital Montluçon
France Poitiers University Hospital Poitiers
France Clinique St André Reims
France Reims University Hospital Reims
France Clinique St Jean Roubaix
France Clinique St Jean Languedoc Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

References & Publications (1)

Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Dutheil JJ, Vielpeau C; PROTHEGE study group; GETHCAM study group. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thromb Res. 2010 Oct;126(4):e298-304. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Thromboembolism occuring between day 7-35 ;
Primary Major bleeding occuring between day 7-35 ;
Primary LMWH induced thrombopenia
Primary All cause mortality
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Active, not recruiting NCT05563883 - Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
Terminated NCT02475187 - Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
Recruiting NCT00982514 - Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 N/A
Completed NCT01420809 - Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection N/A
Terminated NCT00206089 - Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events Phase 3
Completed NCT00014352 - Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Phase 2
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Completed NCT02935751 - Apixaban Discontinuation Prior to Major Surgery
Terminated NCT02579122 - REVIparin-BRIDging-in a General Practice Setting in GErmany
Completed NCT01696760 - Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology N/A
Completed NCT00986154 - Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Phase 3
Terminated NCT00662688 - Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer Phase 3
Completed NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery Phase 2/Phase 3
Terminated NCT00031837 - Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer Phase 3
Completed NCT03877770 - DVT After Cardiac Procedure
Completed NCT00024297 - Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters N/A
Recruiting NCT06118957 - Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery Phase 2